The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Lower pre-transplant serum citrulline level as predictive marker for acute graft-versus-host disease
Armin Rashidi and colleagues from the University of Minnesota, Minneapolis, MN, USA, evaluated serum biomarkers of gut barrier as predictors of allogenic hematopoietic stem cell transplantation (allo-HSCT) outcomes. Three biomarkers (citrulline, regenerating islet-derived protein 3 alpha [Reg3a], and intestinal fatty acid binding protein [I-FABP]) were assessed pre-transplant on day -7, and then post-transplant on days 7 and 28 in consecutive patients undergoing allo-HSCT. The results of the study were published ahead of print in Biology of Blood and Marrow Transplantation on 6 July 2018.
Patients and methods:
- Allo-HSCT recipients: n = 95, median age = 58 years (range, 48–65)
- Controls were healthy donors: n = 16, median age = 51 years (range, 37–56)
- Assessed biomarkers:
- Citrulline: total functional enterocyte mass
- Reg3a: antibacterial activity of the gut
- I-FABP: enterocyte turnover
Key findings:
Biomarkers
- Pre-HSCT biomarker levels were significantly different in patients vs controls:
- Citrulline: 1.88 (1.23–3.31) vs 10.8 (9.05–11.9) ng/mL, P < 0.01
- Reg3a: 7.07 (4.81–11.30) vs 4.70 (3.46–7.40) ng/mL, P = 0.006
- I-FABP: 1.36 (0.78–1.83) vs 0.93 (0.74–1.18) ng/mL, P = 0.03
- Intensity of the most recent preconditioning management, underlying disease, or HSCT-CI did not show correlation with pre-HSCT biomarkers
- I-FABP and Reg3a showed a weak correlation: r = 0.23 (95% CI, 0.03–0.42)
Transplant outcomes and acute graft-versus-host disease (aGvHD)
- Median follow-up = 12 months
- 1-year non-relapse mortality (NRM): 13%, respectively
- Higher Reg3a at day +7 predicted higher non-relapse mortality: 11.51 (9.43–19.99) vs 4.20 (2.76–6.42) ng/mL, P < 0.001
- 6-month aGvHD grade II-IV: 51%, respectively
- Lower pre-HSCT citrulline correlated with higher risk of aGvHD grades II–IV: 1.64 (0.99–2.30) vs 2.70 (1.50–4.41) ng/mL, P < 0.01
- Lower pre-HSCT citrulline level independently associated with a higher risk of aGVHD grade II-IV: HR = 1.32 (95%CI, 1.03–1.69), P = 0.02
Rashidi and colleagues concluded that these findings support that pre-HSCT serum citrulline level can serve as a predictive marker for patients with high risk for developing acute graft-versus-host disease. They further added that their results “suggest that pre-HSCT interventions to augment the gut barrier may decrease the risk of aGvHD.”
References